|
|
|
|
Bio Technology in Karnataka Introduction Biotech can be defined as any technique, product or process which uses or is derived by using any living system (plant, animal or micro-organism), to make or modify a product, to improve plants or animals, or to develop microorganisms for specific use. After establishing itself as a IT and BPO hub, Karnataka has successfully attracted the BioTech industry. As of Q1 2004 Bangalore currently houses 92 of India's 180 biotech companies, with total actual investments of over Rs 1,000 crore, of which Rs 140 crore has been venture capital funding. The companies are encouraged to invest thanks to the presence of large R&D institutions like Indian Institute of Science and the National Centre for Biological Resources. However, it is sure to face a lot of competition from media savvy Hyderabad. Bangalore Helix Bangalore Helix is a biotech cluster being planned by the Karnataka government. Bangalore Helix would support biotech units with common infrastructure. It would comprise eight biotech incubators, covering a total area of 10,000 square feet. Excluding the cost of land (around Rs 60 crore) that has already been acquired, the cluster will involve an investment of Rs 100 crore. The infrastructure support would be comprehensive, right from advance computing facilities to treated water necessary for biotech research. The incumbents of Bangalore Helix would pay for the infrastructure services. Some of the well known companies are: Companies that provide equipment and solutions for the biotech industry Related sites News - Biocon to buy US firm for $400 mn
After gaining a foothold in the European market with the acquisition of German drug marketing firm AxiCorp GmbH in February, India’s Biocon Ltd now has set its sights on the US pharma distribution market with a deal valued at about $400 million (Rs1,595 crore).
The Bangalore-based biotech firm has been scouting for an acquisition in the US that will sell its pharmaceutical products such as generics, biosimilars and biologics in the world’s largest drug market.
- Biocon to acquire Germany-based firm for Rs173 cr
Biotech major Biocon on Monday said it will acquire a majority stake in a Germany-based pharmaceutical company for about 30 million Euros (over Rs173 crore).
Biocon said in a filing to the Bombay Stock Exchange that it has entered into an agreement to acquire the company AxiCorp GmbH, for making it a subsidiary of the former.
- Biocon's revenue up by 21 pc in 2007-08 Q3
The city-based Biocon Limited's consolidated revenues surged by 21 per cent to Rs 811 crore after excluding the Enzymes business, in the third quarter ending December 31, against the corresponding period last year.
Consolidated Operating Profits (EBITDA) increased by 20 per cent to Rs 240 crore. Profit after Tax (PAT) touched Rs 160 crore, which is a 15 per cent rise, BIOCON said in a release here today. The third quarter of the current fiscal registered a one time exceptional pre-tax gain of Rs 330 crore attributable to the divestment of the Enzymes business.
- Biocon to market drug for breast cancer
Biotechnology major Biocon Ltd has announced that it had received the approval to market ABRAXANE, an injectable suspension, in India for the treatment of breast cancer.
Talking to newspersons here, after announcing the half yearly results of the company yesterday, CMD Kiran Mazumdar-Shaw said the drug manufactured by Abraxis BioScience Inc of the US had been approved by the country's Drug Controller General.
- Biocon reports PAT of Rs 107 crore in H12007-08, Revenue Rs 553 cr
Reporting a 27 per cent growth in net profit, biotech major Biocon Limited today annmounced a revenue of Rs 553 crore and a net profit of Rs 107 crore for the first half of the current fiscal.
Consolidated Revenues grew by 19 per cent over the same period in the previous year. Research Services (Syngene) continued to deliver a robust dollar denominated growth of 60 per cent and an impressive 43 per cent based on Rupee realisation. Profit was restrained by rupee appreciation, the Company said in a release..
- Bioscience Park to come up in Electronic City
The Silicon volley of India, Bangalore will add another feather to its cap when Bio-Science Park built at a cost of USD 120 Million comes up in the Electronic City here. Karnataka government would shortly issue the work order to US-based Alexandria Real Estate Equities Inc, which specialises in medical and science laboratories, to build the Bioscience Park.
- Indian Biotech exports up by 47per cent
The Indian Biotech industry gaining worldwide recognition posted a export revenue of Rs 4,937 crore (USD 1.2 billion) in Fiscal 2007, growing by 47 per cent over the previous year. The Industry which notched up a total revenue of Rs 8541 crore saw 27 per cent of it being contributed by top three biotech companies--Pune based Serum Institute (Rs 951 crore), Bangalore head quartered Biocon (Rs 823 crore) and the New Delhi based Panacea Biotech (Rs 600 crore). This was revealed by the fifth industry survey conducted by speciality magazine BioSpectrum of the CyberMedia Group along with the Association of Biotechnology Led Enterprises (ABLE).
- Proj to boost agribiotech on cards by Centre
The Union Department of Biotechnology is contemplating a massive boost to Agribiotech taking up a huge project worth over Rs.1000 crore to give a fillip to stagnant agricultural production.
- Bangalore Bio to showcase India's biotech progress
Complementing the rapid growth of the IT industry in India's silicon city, the emerging biotechnology (BT) sector will look for investments through partnerships and joint ventures at Bangalore Bio 2007, the three-day annual event beginning Thursday.
- Importing trained talent is a costly affair: Kiran
The booming biotech industry was currently suffering from a lack of trained manpower and had been forced to resort to importing talent, which was proving to be a very expensive affair, Chairman and Managing Director Biocon Ltd, Kiran Mazumdar Shaw said.
- Biotech industry to set up finishing schools
Facing an acute shortage of trained manpower, the Biotech industry in the country is now contemplating joining academic institutions to set up finishing schools to tone up the skills of graduates. The first such venture would be with a local educational group People's Education Society, Karnataka Biotechnology Vision Group Chairperson Kiran Mazumdar Shaw told newspersons here today.
- Leading Asia-Pacific Biotech meet on June 7
Growing in size and strength every year, the premier Biotech event of the country, Bangalore Bio 2007 will kick off here on June seven with over 150 companies from 12 countries participating in the much sought after event of the Asia Pacific region.
- Chidambaram to inaugurate Bangalore Bio 2007
Union Finance Minister P Chidambaram will inaugurate the seventh edition of Bangalore Bio 2007 to be held here from June Seven to Nine.
- Preparation in full swing for 'Bangalore Bio 2007'
Key issues which determines the future of Biotechnology industry will be dealt in detail during the Seventh edition of India's biggest biotech event Bangalore Bio 2007, to be held in the city from June seven to nine. 'Think BIG, Think Biotechnology, Think Innovation, Think Growth' would be the focal theme of the this year's mega event. A Conference titled 'Accelerating BT Industry growth through Integrated Innovation,' would be held during the three-day event.
- Biocon declares 25pc increase in turnover for 2007
Biotech major Biocon today reported a 25 per cent increase in its turnover for Fiscal 2007 at Rs 990 crore with net profit up by 15 per cent at Rs 200 crore. The Board which met here today also recommended a 60 per cent dividend (Rs three per share).
- Biocon subsi ties up with Bristol-Myers Squibb
Integrated biotechnology firm Biocon on Wednesday said its subsidiary Syngene has entered into a research partnership with global pharma major Bristol-Myers Squibb. Through this symbiotic global partnership, Biocon's Syngene would provide research and development (R&D) services for discovery and early drug development.
- Biocon forays into nephrology space
Biotechnology major Biocon on Thursday forayed into the nephrology space with the launch of a portfolio of five renal therapy products for the domestic and global markets, which it said was cheaper compared to MNC drug prices.
- Biotech Industry face manpower shortage
The flourishing Biotech industry, which witnessed a astounding growth rate of more than 30 per cent during the last three years, might face a break in its accelerated growth with manpower shortage acting as a spoilsport growth.
- Bangalore Bio 2007 to focus on innovation, growth
Bangalore Bio-2007, the country's flagship biotech event promoted by Karnataka Government to be held between June seven to nine here, would have a focal theme titled 'Think Big' that focusses on innovation and growth of the emerging sector.
- Biocon's Shaw looks at acquisitions in IPRs, marketing
Biocon Ltd is going to focus on acquisitions abroad purely for strategic reasons in either intellectual property assets or for marketing and distribution. Speaking to ET.com, Kiran Mazumdar-Shaw, CMD of Biocon, specified that for her company, the M&As will essentially be based on a strategic reason. She pointed out that Indian companies had different reasons for acquiring a global company, but said very few companies today are doing it simply for expanding the footprint.
- Biocon to invest dollar 10 mn on expansion
Leading biotech firm, Biocon Ltd, on Tuesday said it will invest $10 million (about Rs 45 crore) in the next 12 months to expand its facilities.
- Biocon may launch new anti-arthritis drug
Leading biotech company, Biocon Limited on Monday said it expects to launch a new anti-arthritis drug in the next 3-4 years in the market, which could prove to be a multi-billion dollar opportunity for the company.
- A biotech park soon
Bangalore's tech status is set to receive yet another shot in the arm with the state government deciding to wrap up work on the first phase of the biotechnology park in nine months' time.
- Biocon reports robust first half 2006 results
Biotech major Biocon today reported a robust growth in the first half of the current fiscal, with revenues crossing Rs 463 crore and profit after tax touching Rs 84 crore. Company Chairperson Kiran Mazumdar Shaw told newspersons here that the consolidated sales of the group grew by 23 per cent, with the PAT margin registering a healthy 18 per cent increase.
- Biocon signs agreement with Bayer
Biotech major Biocon Limited announced on Wednesday a licensing agreement with multinational healthcare corporation Bayer HealthCare (BHC) for exclusive marketing and trademark rights for INSUGEN, a recombinant human insulin, for the Chinese market.
- Biocon to market cancer drug in India
India's largest biotechnology firm, Biocon Ltd. , said on Wednesday the Drug Controller General of India had granted approval to market its BIOMAb EGFR treatment for head and neck cancer in India.
- Serum beats Biocon to become top biotech company
The 4th BioSpectrum-ABLE Biotech Industry Survey done in April-May 2006 shows that the industry has attained the critical momentum and is bullish. For the third year in a row, the industry has clocked growth in excess of 35 percent. In 2005-06, the industry grew by 37.42 percent to record $ 1.45 billion (Rs 6,521 crore) in revenue. The industry recorded 36.5 percent growth to cross the $ 1 billion in 2004-05.
- BT business turnover surges up 35 pc: Biocon
Notwithstanding the perceived lack of medical infrastructure, the business turnover in the biotechnology sector of the country crossed over 1.5 billion US Dollar during 2005-06, registering a 35 per cent growth over the previous year, BT major Biocon Ltd Chairperson and Managing Director Kiran Mazumdar-Shaw informed today.
- Sibal calls for greater investment in drug development
Union minister for Science and technology Kapil Sibal said the government was committed to help the biotech industry in developing new drug through public-private partnership and urged the industry to invest in drug development in a big way.
- India emerging player in Biotech
The United Kingdom, which has a strong base for life sciences and Bio-sciences, will offer a greater opportunity to work in tandem with the Indian scientists who have won accolodes at the global level in the field of Biotechnology and its related areas, Sir, Michael Arthur, British High Commissioner to India, said here today.
- Biotech sector to generate 1 mln jobs by 2010: Kiran Mazumdar
Bangalore, June 6 (UNI) The bio-technology sector in the country is expected to generate over a million jobs in agriculture, pharmaceutical and medical segments by 2010, BT major Biocon India Chairperson and Managing Director Kiran Mazumdar-Shah said today. Briefing newspersons before the sixth edition of the three-day international mega event Bio-2006 from June seven here, she said the sector had the potential to touch business worth over five billion dollars by 2010.
- Bangalore Bio begins on June 7
The sixth issue of Bangalore Bio, the annual biotechnology show of the Karnataka Government, kicks off on Wednesday on the promising note of 30-40 per cent growth rate for the domestic biotech industry.
- Karnataka Cabinet approves setting up of Bio Tech Park
The Karnataka Cabinet today approved setting up of a Bio Tech Park at a cost of Rs 103 crore, Minister for Transport Chaluvarayaswamy said today. Briefing newspersons after a Cabinet meeting here, he said that Buildings would be constructed for Institute of Bioinformatics and Applied Biotechnology (IBAB) and the Center for Human Genetics (CHG) and Administrative Building for Karnataka Biotech Training Society (KBITS), which are currently functioning in rented buildings.
- Germany to scout partners at Bangalore Bio
India's leading biotechnology show, Bangalore Bio, commencing its sixth edition on June seven, will see leading players in the field from Germany seeking partners in India during the Business-to-Business event.
- Biotech meet in Bangalore from June 7
The State-sponsored sixth biotechnology event, Bangalore Bio 2006, will have a significant German presence, according to an official release. Participants at the three-day conference and trade fair beginning on June 7 are biotech databases and tools company Biobase; Senova, BASF Plant Science, Roche Diagnostics, Bio Nord, among others.
- Biocon seeks DCGI approval for drug
Biotechnology major Biocon Ltd will seek Drug Controller General of India's approval for its novel monoclonal antibody indicated towards the treatment of head and neck cancer, Biomab EGFR.
- Pricing pressure knocks off 12% from Biocon bottom line
Pricing pressure, impact of higher taxes and depreciation has knocked off 12per cent from Biocon’s bottomline for fiscal 2005-06. The country’s only listed biotech entity on Thursday reported a net profit of Rs 174 crore on a consolidated basis as against Rs 198 crore in the previous fiscal, a drop of 12per cent.
- Biocon files cancer drug Biomab with the DCGI
The Bangalore-headquartered biotech major Biocon has made a filing with the Drug Controller General of India seeking okay for its latest anti-cancer drug Biomab EGFR, which is a monoclonal anti-body for the treatment of cancer in head and neck.
- Karnataka cancels Biocon licence
- Karnataka refers Biocon's procedural lapse to DCGI
- Biocon buys US drug co for $5m
- Biocon faces probe on drug import
- After meeting CM, Bio Queen Kiran Mazumdar Shaw softens stand on government
- After Infy, Biocon boss slams state govt for infrastructure
- Biotech needs skilled professionals
- Biotech faces skill crunch
- Biotechnology is future of India: Thimmappa
- Belgaum to have a biotechnology park soon
- Biocon's US partner, Nobex Corporation, files for bankruptcy
- Biocon signs agreement with Bentley
- Fortune favors Kiran Mazumdar-Shaw
- Biocon chief stresses on corporates' social role
- Biocon readies EU plans for insulin
- BT industry shuns BU graduates
- Biocon set to hire 2,000 more in 2 years
- Biotech symposium harps on basics
- MAHE honours Biocon CEO with Doctorate
- Doctors should change their mindset: Biocon chief
- IT, BT will remain in Bangalore: Karnataka CM
- IT, BT policy draws CAG ire
- Mysore firm Labland Biotechs to export Jatropha
- Bangalore biotech park work to begin in June
- 50% of country's biotech firms based in Karnataka
- Biotech turnover could touch $5 bn by '10: Kiran Mazumdar Shaw
- Wipro tool for bio-computing
- This brewmaster decided to brew a biotech empire
- Bio Queen Kiran Mazumdar Shaw conferred Padma Bhushan Kudos!
- WestBridge Capital invests $1.5 mn in Series A1 equity in ReaMetrix
- Biocon research product to hit market in a year
- Biocon to develop oral insulin
- Insugen not to upset US, Europe price applecart
- Biocon ties up with Vaccinex for antibody products
- Biocon plans foray into oncology, to launch new molecule Theracim
- Biocon's cancer drug by 2005-end
- Biocon's 'Insugen' to target 100 mn diabetics worldwide
- Biocon launches portal on diabetes - insugen.com
- Biocon to acquire stake in 2 US firms, Nobex & Vaccinex
- BioQueen Kiran Mazumdar Shaw sees Bangalore busting
- Biocon's cancer drug enters phase II trials
- Is Bangalore really a biotech hub wonders US scientist
- BioTech parks a boost for research companies: BioQueen Kiran Mazumdar-Shaw
- Biocon injects new intiative on insulin
- Biocon's Data Goes Online For Transparency
- Sindhia claims Biocon will start new unit in Hassan, BioQueen Kiran says NO
- Biocon featured in "India Biotechnology Handbook"
- Biocon Biopharmaceuticals expands product base
- German company, Boehringer Ingelheim may start operations in Bangalore
- Spend more on biotechnology: Indian Institute of Science
- Biotech star Biocon throws a challenge to IT - Kudos Madam!
- Biocon Seeks GEAC Nod For Human Insulin
- Biocon logs 109% rise in Q1 net profit to Rs 43.7 crore
- German genomics major MWG sets shop in Bangalore
- Biocon gets starting, bets big for '06
- Lower costs could make India an ideal biotech hub
- Biotech boom calls for informatics solutions
- Bangalore Bio-2004 draws 50,000 visitors
- Strand Genomics Unveils Bioinformatics Tool
- State leader in biotechnology: Deputy CM
- Bio-informatics courses to be offered in city
- Centre to sow new biotech policy
- Karnataka State sanctions Rs 10 cr for 100 acre Biotech Park
- BT industry cries for funds, govt backing
- Biotech to generate a million jobs by 2010
- Karnataka to attract Rs 1,000 crore in BT
- Karnataka Biotech Development Council (KBDC) to tie up with Frankfurt Innovation Centre
- Bangalore Bio Begins Tomorrow
- Karnataka blares BT, mum on IT
- Lifestyle drugs turn thrust area for Biocon
- Biocon to market statins in dosage forms
- Strand Genomics launches Avadis 3
- Biocon India and CIMAB SA of Cuba JV Adds New Products To Portfolio
- Glentec Int hike stake in Biocon Ltd
- AstraZeneca to scale up Indian business in Bangalore
- Future of task forces worries Bangalore Inc
- Avesthagen Eyes Biopharma R&D
- US based Concerto Outlines Big Plans For Bangalore
- Kiran calls for one-stop body for biotech
- Biocon chief outlines path to global recognition
- Biocon bonanza may revive ESOP debate
- Biocon management now super-rich
- Biocon becomes billion-dollar company on listing day
- Kiran Mazumdar Shaw: India's wealthiest woman, worth Rs 1,800 crore (she deserves to be!)
- Blair bowled over by City's biotech sharks
- Biocon IPO Gets Rs 10,400-crore Investor Commitment
- Biocon issue oversubscribed 27 times
- It's Time For Biotech Blitz At Infosys
- Biotech Sector Asks Govt For Rs 200 Cr Fund For Start-ups: Kiran Mazumdar
- Biocon plans new unit for Cuban JV
- Biocon a good buy, but expensive: Analysts
- Bangalore: Silicon Valley or Coolie Valley?
- Biocon IPO priced at Rs 270-315
- Biocon files insulin DMF, ties up with Bristol-Myers
- Biotech: it's Hyderabad vs Bangalore
- Annual biotech expo postponed to May 16 for elections
- Biotech Market Set To Touch $9 B By 2010: Kiran Mazumdar-Shaw
- BioSpectrum Awards 2003
- BT bucks: Biocon India pays it big to top brass
- Biocon files draft red herring prospectus
- Biocon net rises to Rs 95 cr in 9 months
- Biocon to emerege as leading biotech player
- Bicon's human insulin to be ready by March 2004
- Biocon to emerege as leading biotech player
- Biocon Readies Human Insulin; To Tap Indian Market By 2004
- 'Bee corridor' to come up at BT park
- Bio-technology Park will be hub of research activities
- India, US to identify joint projects in biotechnology
- Govt not pro-active: Biocon chief
- Bangalore biotech park work to start on Nov 1
- I agreed to start Biocon on an impulse: Kiran Shaw
- Astra Zeneca CEO To Open $11 M TB R&D Facility In Bangalore
- TCS developing bioinformatics software on Linux
- Karnataka to float biotech fund to rope in VCs
- Vivek Kulkarni: Meet the brain behind Bangalore Bio
- InfoPro expanding Bangalore unit
- Biogenus To Invest $20 M In Karnataka Research Project
- Karnataka invites bids for bio-park
- Biotech will see explosive growth: CII
- Biotech in 10 more Bangalore University colleges
- India well positioned to knock out China
- BT venture capitalists root for Karnataka
|
|
|
|
| |
|
|
| |
|
|
|
|
